Biologic Therapy

The FDA has granted a fast track designation to rezpegaldesleukin for treating patients aged 12 years and older with moderate to severe atopic dermatitis that topical therapies have not adequately controlled, according to a press release.

Published results showed the use of a novel bioresorbable scaffold-anchor to augment healing after rotator cuff repair may not yield clinically superior outcomes compared with a standard anchor.

Uptake of belimumab continues to outpace the use of anifrolumab among clinicians managing patients with systemic lupus erythematosus, according to a survey conducted by Spherix Global Insights.

Healio highlights the most-read research, topics and news in orthobiologics in 2024.

Percutaneous orthobiologic treatment may be an effective alternative to home exercise therapy for treatment of rotator cuff tears, according to results published in BMC Musculoskeletal Disorders.

In light of a “significant expansion in the therapeutic armamentarium” for moderate to severe ulcerative colitis, the AGA has released an updated living clinical practice guideline of patient-centered pharmacological interventions.

WASHINGTON — Biosimilar infliximab use is significantly more common among new users vs. those who started with the originator, and particularly less likely among Medicare beneficiaries, according to data presented at ACR Convergence 2024.

Healio has compiled October’s most read news in asthma and allergy.

BOSTON — Physicians can take a deep dive into the current state of asthma care as the American College of Allergy, Asthma & Immunology opens its 2024 conference on Thursday, Oct. 24, with a full day dedicated to diagnosis and treatment.